LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended): A method for conferring resistance to endotoxic shock in an animal in need of resistance to endotoxic shock, comprising administering to ~~an~~ said animal a composition having a physiologically effective amount of at least one OB-R agonist ligand.

2. (Original): The method of claim 1 wherein the OB-R agonist ligand is recombinant human OB protein.

3. (Original): The method of claim 2 wherein the amount of recombinant human OB protein administered is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

Claims 4-5 (Canceled)

6. (Previously presented): The method of claim 1 wherein the endotoxic shock occurs in sepsis.

7. (Previously presented): The method of claim 1 wherein the endotoxic shock occurs in systemic inflammatory response syndrome.

Claims 8-17 (canceled)

18. (Previously presented): A method for the treatment of a patient having obesity comprising the steps of:

administering at least one compound capable of inducing OB-R expression selected from the group consisting of LPS, IL-1α, IL-1β, TNF-α and IL-6; and

administering a physiologically effective amount of an OB-R agonist ligand.

Claim 19 (Canceled)

20. (Previously presented): The method of claim 18 wherein the compound and the OB-R agonist ligand are administered at different times.

21. (Previously presented): The method of claim 18 wherein the compound is administered in an amount from about 0.003 to about 20 micrograms per kilogram body weight.

22. (Original): The method of claim 18 wherein the OB-R agonist ligand is administered in an amount from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

23. (Original): The method of claim 18 wherein the OB-R agonist ligand is recombinant human OB protein.

24. (Original): The method of claim 23 wherein the recombinant human OB protein is administered in an amount from about 1 micrograms per kilogram body weight to about 50 micrograms per kilogram body weight.

Claim 25 (Canceled):

26. (Previously presented): The method of claim 18 wherein IL-6 is administered in an amount from about 0.5 to about 20 micrograms per kilogram body weight.

27. (Previously presented): A method for inducing OB receptor expression in an animal, comprising the steps of:

administering to the animal IL-6 in an amount from about 0.5 to about 20 micrograms per kilogram body weight; and

administering to the animal recombinant OB protein in an amount from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

28. (Original): A composition suitable for the treatment of obesity comprising:

at least one therapeutic cytokine capable of increasing the expression of the OB receptor;

a physiologically effective amount of an OB-R agonist ligand; and a pharmaceutically acceptable excipient.

29. (Original): The composition of claim 28 wherein the therapeutic cytokine capable of increasing the expression of the OB receptor and the OB-R agonist ligand are packaged separately.

30. (Original): The composition of claim 28 wherein the therapeutic cytokine is about 0.5 to about 20 micrograms per kilogram body weight IL-6.

31. (Original): The composition of claim 29 wherein the OB-R agonist ligand is administered in a dose of about 1 micrograms per kilogram body weight to about 50 micrograms per kilogram body weight recombinant human OB protein.

Claims 32-35 (canceled)